Cargando…

Good Enough? Terlipressin, Hepatorenal Syndrome, and the Usage of RRT

Detalles Bibliográficos
Autor principal:	Belcher, Justin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Nephrology 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484352/ https://www.ncbi.nlm.nih.gov/pubmed/37651662 http://dx.doi.org/10.34067/KID.0000000000000217

Ejemplares similares

Hepatorenal syndrome:Response to terlipressin and albumin and its determinants
por: Sarwar, Shahid, et al.
Publicado: (2016)

The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome
por: Velez, Juan Carlos Q., et al.
Publicado: (2023)

An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome
por: Bui, Thi Ngoc Nhieu, et al.
Publicado: (2020)

Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis
por: Wang, Haiqing, et al.
Publicado: (2018)

Terlipressin effect on hepatorenal syndrome: Updated meta‐analysis of randomized controlled trials
por: Mohamed, Mohamed M G, et al.
Publicado: (2021)

Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile
por: Ayyad, Ahlam, et al.
Publicado: (2023)

Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome
por: Kim, Hae Rim, et al.
Publicado: (2013)

Terlipressin-Induced Peripheral Cyanosis in a Patient with Liver Cirrhosis and Hepatorenal Syndrome
por: Chiang, Chi-Wen, et al.
Publicado: (2019)

The Current Management of Hepatorenal Syndrome–Acute Kidney Injury in the United States and the Potential of Terlipressin
por: Flamm, Steven L., et al.
Publicado: (2021)

Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: A meta-analysis
por: Hiremath, Sharanabasayyaswamy B., et al.
Publicado: (2013)

Terlipressin versus Norepinephrine in the Treatment of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis
por: Nassar Junior, Antonio Paulo, et al.
Publicado: (2014)

Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response?
por: Altun, Reskan, et al.
Publicado: (2015)

Real‐world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome
por: Moore, Kevin, et al.
Publicado: (2020)

Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function
por: Huang, Xingyue, et al.
Publicado: (2023)

Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies
por: Curry, Michael P., et al.
Publicado: (2023)

Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence
por: Bai, Zhaohui, et al.
Publicado: (2020)

Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial
por: Karvellas, Constantine J., et al.
Publicado: (2023)

Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure
por: Wong, Florence, et al.
Publicado: (2022)

Terlipressin-Induced Skin Necrosis While Managing Hepatorenal Syndrome: A Rare Case Report From North India
por: Sudan, Sourav, et al.
Publicado: (2023)

A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug
por: Thangaraj, Santhosh Raja, et al.
Publicado: (2023)

Commentary: Metabolic syndrome and the hepatorenal reflex
por: Wider, Michael D.
Publicado: (2016)

Hepatorenal syndrome: Update on diagnosis and therapy
por: Acevedo, Juan G, et al.
Publicado: (2017)

Endothelin-1/Nitric Oxide Ratio as a Predictive Factor of Response to Therapy With Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome
por: Abdel-Razik, Ahmed, et al.
Publicado: (2020)

Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis
por: Belcher, Justin M., et al.
Publicado: (2015)

Because good enough is never good enough
por: John, M
Publicado: (2012)

Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study
por: Kulkarni, Anand V., et al.
Publicado: (2022)

CONFIRMing Hepatorenal Syndrome Management: #NephJC Editorial
por: Willows, Jamie, et al.
Publicado: (2021)

Following the MAP for Improved Kidney Function in Hepatorenal Syndrome
por: Thau, Matthew R., et al.
Publicado: (2023)

Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
por: Velez, Juan Carlos Q., et al.
Publicado: (2023)

Health professionals' advice for breastfeeding problems: Not good enough!
por: Amir, Lisa H, et al.
Publicado: (2008)

“Available upon request”: not good enough for microbiome data!
por: Langille, Morgan G. I., et al.
Publicado: (2018)

Hepatorenal Syndrome
por: Kiser, Tyree H.
Publicado: (2014)

Care of Patients With Chronic Kidney Disease Presenting With Acute Coronary Syndrome: Improved, But Not Good Enough
por: Hira, Ravi S.
Publicado: (2018)

Belatacept: Good, but not good enough?
por: Parameswaran, Sreejith, et al.
Publicado: (2012)

Terlipressin or Europressin?
por: Leone, Marc
Publicado: (2009)

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT‐0401 and REVERSE randomised clinical studies
por: Sanyal, A. J., et al.
Publicado: (2017)

Enough is enough
por: Borowski, Christine
Publicado: (2011)

Good enough practices in scientific computing
por: Wilson, Greg, et al.
Publicado: (2017)

NOT "Good Enough for the War."
Publicado: (1916)

Good-Enough Synthesis
por: Almagor, Shaull, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kb42k2j0mcenrq98vcj1o1egfq